USA flag logo/image

An Official Website of the United States Government

E. COLI QUIESCENT SYSTEMS FOR MAMMALIAN EXPRESSION OF UNCLONABLE DNA

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89275
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
HG004814
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
LUCIGEN CORPORATION
2905 PARMENTER ST. Middleton, WI 53562-2547
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: E. COLI QUIESCENT SYSTEMS FOR MAMMALIAN EXPRESSION OF UNCLONABLE DNA
Agency: HHS
Contract: 1R43HG004814-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): A complete and accurate collection of all expressed genes is critical for genomic and proteomic research of any genome. However, despite significant efforts to clone all the expressed human genes, approximately 20% of the predicted protein-coding genes are incomplete or not found in reference cDNA collections. The instability or toxicity of numerous protein-coding genes in E. coli is likely to play a major role in this problem. The goal of the current research proposal is to develop linear and circular shuttle vectors to clone these otherwise unclonable genes into E. coli and mammalian cells. The vectors will be transcriptionally silent in E. coli, but they will allow active expression in mammalian cells. A new linear vector that shows high stability for cloning otherwise unstable DNAs will be modified to prevent fortuitous expression in E. coli. Further, it will be coupled with signals to direct mammalian transcription and translation. A major benefit of this project i s that it will allow researchers to obtain and express a wide variety of genes from the human and other genomes that are currently unclonable . Such genes are likely to have large coding regions (e.g., gt10 kb), unusual base composition, or repetitive seq uences. Significantly, these vectors will allow analysis of unstable regions of the human genome, which are the cause of numerous heritable diseases. Future derivatives will include systems specifically for bacterial expression of large, toxic, or unstable cDNAs. PUBLIC HEALTH RELEVANCE: A complete and accurate collection of expressed genes is critical for genomic and proteomic research of any genome. Despite significant efforts to discover and clone all the expressed human genes, approximately 20% of the potential protein-coding regions are incomplete or not found in reference cDNA collections. The inability to clone numerous protein-coding genes into E. coli is likely to play a major role in this problem. The goal of the current research proposal is to d evelop linear and circular shuttle vectors to clone otherwise unclonable genes for expression in mammalian cells. The vectors will be transcriptionally silent in E. coli, but active in mammalian cells. A new linear vector that shows high stability for cl oning otherwise unstable DNAs will be modified to prevent fortuitous expression in E. coli. Further, it will be coupled with signals to direct mammalian transcription and translation. A major benefit of this project is that it will allow researchers to clo ne genes that have large coding regions (e.g., gt10 kb), unusual base composition, or repetitive sequences. Future research will include the development of similar vectors specifically for prokaryotic expression of large or toxic cDNAs.

Principal Investigator:

Business Contact:


dmead@lucigen.com
Small Business Information at Submission:

LUCIGEN CORPORATION
2120 W. GREENVIEW DR. SUITE 9 MIDDLETON, WI 53562

EIN/Tax ID: 391923306
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No